DSM-Firmenich AG (DSFIY)
| Market Cap | 20.75B -23.4% |
| Revenue (ttm) | 15.28B +4.5% |
| Net Income | 843.22M |
| EPS | 3.19 |
| Shares Out | n/a |
| PE Ratio | 24.61 |
| Forward PE | 19.27 |
| Dividend | 0.22 (2.79%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 161 |
| Average Volume | 611,553 |
| Open | 8.25 |
| Previous Close | 8.46 |
| Day's Range | 8.24 - 8.43 |
| 52-Week Range | 7.62 - 11.57 |
| Beta | 0.89 |
| RSI | 56.34 |
| Earnings Date | Feb 12, 2026 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and s... [Read more]
Financial Performance
In 2024, DSM-Firmenich AG's revenue was 12.80 billion, an increase of 20.44% compared to the previous year's 10.63 billion. Earnings were 250.00 million, a decrease of -88.27%.
Financial numbers in EUR Financial StatementsNews
DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript
DSM-Firmenich AG (DSFIY) Shareholder/Analyst Call Transcript
dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH)
Press Release dsm-firmenich provides preliminary comparative figures following the announced divestment of Animal Nutrition & Health (ANH) Kaiseraugst (Switzerland), Maastricht (Netherlands), February...
DSM-Firmenich to Sell Animal Nutrition Unit to CVC in $2.6 Billion Deal
The sale to CVC Capital Partners marks the final step in its plan to fully focus on human nutrition, health and beauty.
DSM-Firmenich to sell animal health business to CVC Capital
Chemicals company DSM-Firmenich has agreed to sell its Animal Nutrition & Health business to CVC Capital for an enterprise value of around 2.2 billion euros ($2.6 billion), it said on Monday.
dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners
Press Release dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners Kaiseraugst (Switzerland), Maastricht (Netherlands), February 9, 2026 dsm-firmenich, innovat...
dsm-firmenich appoints Nikeisha van Sleeuwen as Chief Human Resources Officer
Press Release dsm-firmenich appoints Nikeisha van Sleeuwen as Chief Human Resources Officer Kaiseraugst (Switzerland), Maastricht (Netherlands), January 14, 2026 dsm-firmenich, the leading innovator i...
Goldman Sachs International Equity ESG Fund Q3 2025 Portfolio Review
Goldman Sachs International Equity ESG Fund initiated a position in ING Group (2.6%), a Dutch global financial institution. We initiated a position in Air Liquide (2.0%), which produces, markets, and ...
DSM-Firmenich: High-Quality Value Play
DSM-Firmenich, formed by the merger of DSM and Firmenich, faces challenges post-merger, including the sale of the ANH division. The stock has experienced a significant price decline, presenting a pote...
DSM-Firmenich AG (KDSKF) Q3 2025 Sales Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q3 2025 Sales Call October 30, 2025 4:00 AM EDT Company Participants Dave Huizing - Senior Vice President of Investor Relations Dimitri de Vreeze - Chief Executive Officer...
dsm-firmenich Q3 2025 trading update
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), October 30, 2025 dsm-firmenich Q3 2025 trading update Management Report Q3 2025 highlights Solid growth and strong step up in Adjuste...
Artisan International Value Fund Q3 2025 Portfolio Update
Major joint customer announcements about new products and significant future orders combined with strong demand for basic memory semiconductors drove renewed interest in Samsung Electronics stock. ABB...
DSM-Firmenich: A Widening Moat At A Discount
DSM-Firmenich leverages scale, proprietary R&D, and customer stickiness to enhance its position in specialty ingredients, flavors, and fragrances. DSM-Firmenich delivered 7% organic sales growth and a...
dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company
Press Release dsm-firmenich strengthens its Executive Committee for future growth as a consumer-focused company Kaiseraugst (Switzerland), Maastricht (Netherlands), September 1, 2025 dsm-firmenich is ...
DSM-Firmenich AG (DSFIY) Q2 2025 Earnings Call Transcript
DSM-Firmenich AG (OTCQX:DSFIY) Q2 2025 Earnings Conference Call July 31, 2025 3:00 AM ET Company Participants Dave Huizing - Senior Vice President of Investor Relations Dimitri de Vreeze - Chief Execu...
dsm-firmenich reports H1 2025 results
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), July 31, 2025 dsm-firmenich reports H1 2025 results Management Report H1 2025 highlights Good first half of the year, with good organ...
Dsm-firmenich's animal feed unit sale attracts three final bidders, Dutch paper reports
Dsm-firmenich's is close to selling its animal nutrition business, with final bids expected from private equity firms CVC , Apollo and Dutch rival Nutreco, Dutch newspaper Financieele Dagblad reported...
dsm-firmenich announces redemption of €750 million hybrid bond
Press Release dsm-firmenich announces redemption of € 750 million hybrid bond Kaiseraugst (Switzerland), Maastricht (Netherlands), July 1, 2025 dsm-firmenich, innovators in nutrition, health, and beau...
dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion
Press Release dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 27, 2025 dsm-firmenich, innovators ...
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Press Release dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025 dsm-firmenich, innovato...
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025
Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025 dsm-firmenich, innovators in nutrition,...
DSM-Firmenich AG (KDSKF) Q1 2025 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q1 2025 Results Conference Call April 30, 2025 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Ralf Schmeitz - Chief Financial Officer Conference...
Laetitia Pictet appointed Chief Legal, Risk and Compliance Officer of dsm-firmenich
Press Release Laetitia Pictet appointed Chief Legal, Risk and Compliance Officer of dsm-firmenich Kaiseraugst (Switzerland), Maastricht (Netherlands), April 8, 2025 dsm-firmenich, innovators in nutrit...
dsm-firmenich completes shareholding increase in Andre Pectin to 90.5%
Press Release dsm-firmenich completes shareholding increase in Andre Pectin to 90.5% Kaiseraugst (Switzerland), Maastricht (Netherlands), April 3, 2025 dsm-firmenich, innovators in nutrition, health, ...
Human Milk Oligosaccharides (HMOs) Market Insights 2025, Analysis and Forecast to 2030 Featuring Key Companies - DSM-Firmenich, Kyowa Hakko, and Chr. Hansen
Dublin, March 26, 2025 (GLOBE NEWSWIRE) -- The "Human Milk Oligosaccharides (HMOs) Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Produ...
dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day
Press Release dsm-firmenich showcases integrated approach to sustainability and business performance at Sustainability Investor Day Kaiseraugst (Switzerland), Maastricht (Netherlands), March 25, 2025 ...